Institut Pasteur Korea’s Discovery Chemistry group applies new concepts of drug design to optimize hit-to-lead identification. Its drug discovery technology platforms have led to the first-ever TB chemical screen performed using primary macrophages and resulting in a new best-in-class molecule to fight TB, referred to as Q203.
